Icon Plc

NASDAQ:ICLR   3:59:56 PM EDT
230.28
+6.61 (+2.96%)
Products, Regulatory

Evergreen Therapeutics, Inc. Announces Agreement With Icon PLC To Conduct Phase II Clinical Trial For Covid-19 Drug Candidate

Published: 06/18/2021 14:54 GMT
Icon Plc (ICLR) - Evergreen Therapeutics, Inc. Announces Agreement With Icon Plc to Conduct Phase Ii Clinical Trial for Covid-19 Drug Candidate.
Evergreen Therapeutics - First Patients With Covid-19 Are Expected to Be Enrolled in Early August 2021.
Evergreen Therapeutics - Phase Ii Clinical Trial is Expected to Be Completed by Middle of 2022.